Literature DB >> 8391786

Activation of neutrophils by soluble and insoluble immunoglobulin aggregates from synovial fluid of patients with rheumatoid arthritis.

J J Robinson1, F Watson, M Phelan, R C Bucknall, S W Edwards.   

Abstract

OBJECTIVES: Previous work has shown that synovial fluid isolated from patients with active rheumatoid arthritis contains soluble (not sedimented by centrifugation at 11,600 g for two minutes) and insoluble (sedimented by centrifugation at 11,600 g for two minutes) immunoglobulin aggregates that are capable of activating reactive oxidant production by bloodstream neutrophils. The purpose of this study was to determine which of these types of immunoglobulin aggregates activated the secretion of reactive oxygen metabolites and granule enzymes from neutrophils.
METHODS: Cell free synovial fluid (from patients with rheumatoid arthritis) was added to neutrophils isolated from blood of healthy controls that had been incubated in the presence and absence of granulocyte-macrophage colony stimulating factor (GM-CSF). Reactive oxidant production was measured by luminol chemiluminescence (which detects both intracellular and extracellular oxidant production) and by cytochrome c reduction (which measures superoxide secretion).
RESULTS: The soluble aggregates only activated neutrophils that were previously primed, and activated a rapid and transient burst of reactive oxidant secretion. On the other hand, the insoluble aggregates activated primed and unprimed neutrophils with similar efficacy and most of the oxidants generated (especially in unprimed cells) were intracellular. The soluble aggregates, but not the insoluble aggregates, also activated the secretion of myeloperoxidase from neutrophils that had either been pretreated with cytochalasin B or primed with GM-CSF.
CONCLUSION: It is thus proposed that these soluble immunoglobulin aggregates are responsible for activation of the release of tissue damaging granule enzymes and reactive oxidants from primed neutrophils within the rheumatoid joint.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391786      PMCID: PMC1005048          DOI: 10.1136/ard.52.5.347

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

Review 1.  Oxygen free radicals, inflammation, and synovitis: and synovitis: the current status.

Authors:  P Merry; P G Winyard; C J Morris; M Grootveld; D R Blake
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Oxidative inactivation of myeloperoxidase released from human neutrophils.

Authors:  S W Edwards; H L Nurcombe; C A Hart
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

3.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent.

Authors:  B M Babior; R S Kipnes; J T Curnutte
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

4.  Pattern of formylmethionyl-leucyl-phenylalanine-induced luminol- and lucigenin-dependent chemiluminescence in human neutrophils.

Authors:  C Dahlgren; H Aniansson; K E Magnusson
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

5.  Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis.

Authors:  S W Edwards; V Hughes; J Barlow; R Bucknall
Journal:  Biochem J       Date:  1988-02-15       Impact factor: 3.857

6.  Luminol- and lucigenin-dependent chemiluminescence of neutrophils: role of degranulation.

Authors:  S W Edwards
Journal:  J Clin Lab Immunol       Date:  1987-01

7.  Intra- and extracellular events in luminol-dependent chemiluminescence of polymorphonuclear leukocytes.

Authors:  G Briheim; O Stendahl; C Dahlgren
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  Induction of neutrophil enzyme release by rheumatoid factors: evidence for differences based on molecular characteristics.

Authors:  W D Blackburn; W J Koopman; R E Schrohenloher; L W Heck
Journal:  Clin Immunol Immunopathol       Date:  1986-08

9.  Synovial fluid neutrophils of patients with rheumatoid arthritis have membrane antigen changes that reflect activation.

Authors:  P Emery; A F Lopez; G F Burns; M A Vadas
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

10.  Phagocytosis and intracellular killing of Staphylococcus aureus by polymorphonuclear cells from synovial fluid of patients with rheumatoid arthritis.

Authors:  F C Breedveld; G J Lafeber; M T van den Barselaar; J T van Dissel; P C Leijh
Journal:  Arthritis Rheum       Date:  1986-02
View more
  5 in total

1.  Neutrophils from the synovial fluid of patients with rheumatoid arthritis express the high affinity immunoglobulin G receptor, Fc gamma RI (CD64): role of immune complexes and cytokines in induction of receptor expression.

Authors:  J A Quayle; F Watson; R C Bucknall; S W Edwards
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

2.  Insoluble and soluble immune complexes activate neutrophils by distinct activation mechanisms: changes in functional responses induced by priming with cytokines.

Authors:  G Fossati; R C Bucknall; S W Edwards
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

3.  Role of Fc gamma receptors in the activation of neutrophils by soluble and insoluble immunoglobulin aggregates isolated from the synovial fluid of patients with rheumatoid arthritis.

Authors:  J J Robinson; F Watson; R C Bucknall; S W Edwards
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

4.  Altered Ca2+ signalling in human neutrophils from inflammatory sites.

Authors:  E V Davies; B D Williams; R J Whiston; A M Cooper; A K Campbell; M B Hallett
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

5.  Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases.

Authors:  I Sopata; J Wize; A Filipowicz-Sosnowska; E Stanisławska-Biernat; B Brzezińska; S Maśliński
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.